Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Msci Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Msci Inc trades at $565.12 (market cap $40.38B). The key difference: Msci Inc is far larger — about 6.7× Iovance Biotherapeutics Inc. Common Stock's market cap, and Msci Inc pays a 1.48% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Msci Inc for 82 Days on average.
| IOVA | MSCI | |
|---|---|---|
Market Cap | $6.04B | $40.38B |
Volume | 14,805,993 | 414,140 |
Sector | Health | Financials |
52-Week High | $14.82 | $643.83 |
52-Week Low | $1.81 | $511.84 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $5.97B | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MSCI trades at $561.67, up 1.13% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $3.13B in 2025, with a high net income margin of 40.73%. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow from operations. Analyst consensus is strongly positive, with a $701.71 price target, supported by 74% buy ratings. Key developments include the completed acquisition of First Street, enhancing its climate risk analytics offerings.
The outlook for MSCI is favorable, driven by recurring revenue streams, high client retention, and growth in passive investing and private markets. Risks include high valuation multiples, significant long-term debt of $4.51B, and sensitivity to financial market cycles. The stock presents a long-term growth opportunity, but investors should monitor execution on earnings and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
